menu
    • menu
    [{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Xspray Pharma

    Menu

    Xspray Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024

                            Details : Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.

                            Product Name : Dasynoc

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

                            Details : Xspray Pharma's lead product XS004 (dasatinib) is being evaluated in the late-stage clinical trial studies for treating patients suffering from chronic myeloid leukemia.

                            Product Name : Dasynoc

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna

                            Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.

                            Product Name : XS003

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Xspray Pharma

                            Sweden arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment

                            Details : Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric p...

                            Product Name : Dasynoc

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 30, 2020

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth